April 16, 2008 - U.S. Patent and Trademark Office Grants Biomoda Notice of Allowance for Patent Protection for Additional Intellectual Property –Biomoda, Inc. (OTC Bulletin Board: BMOD) , a development stage medical diagnostics company, announced it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its invention directed to the “Method for Prognosing Response to Cancer Therapy with 5,10,15,20-Tetrakis (Carboxyphenyl) Porphine.” Biomoda’s innovative, non-invasive technology is designed for early lung cancer screening of large populations at a reasonable cost. With the technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope.
Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease at more advanced stages. Biomoda’s technology compliments these tools by screening for signs of lung cancer at an earlier stage, ensuring that patients receive advanced tests at the appropriate time... Biomoda's Press Release -
